Intrexon | XON - 销售和管理费用





销售和管理费用 更改 日
Agenus USD 10.56M 13.04M 2025-12
Alaunos Therapeutics USD 585K 84K 2025-09
Amgen USD 1.58B 354M 2026-03
Anika Therapeutics USD 10.01M 14K 2025-12
Arrowhead Research USD 46.02M 8.84M 2025-12
AstraZeneca USD 5.06B 455M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Gilead Sciences USD 1.78B 425M 2025-12
GlaxoSmithKline GBP 2.12B 558M 2026-03
Heron Therapeutics USD 23.74M 605K 2025-12
Incyte USD 328.1M 62.31M 2026-03
Intrexon USD 10.31M 41K 2024-06
Karyopharm Therapeutics USD 9.56M 17.63M 2025-12
Ligand Pharmaceuticals USD 28.45M 8.27M 2025-09
MacroGenics USD 7.94M 1.96M 2025-12
MannKind USD 29.09M 2.53M 2025-09
Merck USD 2.67B 180M 2026-03
Novartis USD 3.14B 296M 2026-03
Rigel Pharmaceuticals USD 27.04M 1M 2024-09
Roche Holding CHF 7.28B 3.99B 2025-12
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Thermo Fisher Scientific USD 1.8B 179M 2026-03
Veracyte USD 43.31M 8.43M 2025-12
Xencor USD 17.04M 70.74M 2025-12